Third Quarter Highlighted by Initiation of Phase 3 Study of PF614, Underscoring Progress Toward Market Readiness and Commitment to Novel Opioid Solutions ~ ~ Further Program Advancement Supported by ...

International Isotopes Inc. (OTCQB: INIS) (the "Company" or "INIS") is pleased to announce its financial results for the third quarter and nine months ended September 30, 2025. Revenue from the sale ...